On April 30, 2025 Aveta Biomics, a clinicalstage biotechnology company developing first-in-class drugs that reprogram the immune system to fight cancer, reported acceptance of abstract for poster presentation at the 2025 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, taking place May 30 – June 3, 2025, in Chicago, Illinois (Press release, Aveta Biomics, APR 30, 2025, View Source [SID1234652377]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The poster will feature clinical data from the company’s Phase IIA trial evaluating its drug APG157 as a neoadjuvant monotherapy in patients with locally advanced squamous cell carcinoma of the head and neck.
"The acceptance of our Phase IIA data for presentation at ASCO (Free ASCO Whitepaper) marks an important milestone for Aveta Biomics," said Parag Mehta, Ph.D., Chief Executive Officer of Aveta Biomics. "We look forward to sharing the full dataset with the oncology community and advancing APG-157 toward a pivotal trial in head and neck cancer."
"APG-157 has the potential to become a first-in-class, practice-changing neoadjuvant therapy for patients with locally advanced head and neck cancer," said Selda Samakoglu, M.D., Ph.D., Chief Medical Officer of Aveta Biomics. "In our Phase IIA study, APG-157 demonstrated clinically meaningful activity across multiple key endpoints, including survival outcomes, with consistent benefits observed both in the overall patient population and in key subgroups. We look forward to advancing APG-157 into a pivotal trial, with the goal of confirming these promising results and establishing APG-157 as a transformative monotherapy option in this setting."
PRESENTATION DETAILS:
TITLE: Neoadjuvant APG-157 monotherapy in patients with locally advanced squamous cell carcinoma of head and neck: A phase IIA, single arm trial
ABSTRACT NUMBER: 6087
POSTER BOARD 495
SESSION TITLE: Head and Neck Cancer
SESSION DATE AND TIME: June 2, 2025, 9:00 AM – 12:00 PM CDT
PRESENTERS:
• Marilene Wang, M.D., Professor, Department of Head and Neck Surgery, UCLA David Geffen School of Medicine and VA Hospital of Greater Los Angeles
• Elizabeth Franzmann, M.D., Professor, Head and Neck Surgery, University of Miami, Sylvester Comprehensive Cancer Center